Risk of venous thromboembolism and primary prophylaxis in cancer: Should all patients receive thromboprophylaxis?

Hamostaseologie

Volumn 32, Issue 2, 2012, Pages 132-137

  Pabinger, I ^a   Ay, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; FIBRINOGEN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PADGEM PROTEIN; PLACEBO; PROTHROMBIN; TAMOXIFEN; THALIDOMIDE; THROMBIN; WARFARIN; FIBRINOLYTIC AGENT;

AMBULATORY CARE; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOCYTE MICROPARTICLE; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOMA; MELANOMA; MORTALITY; MULTIPLE MYELOMA; NEOPLASM; NEUROSURGERY; PANCREAS TUMOR; PLATELET MICROPARTICLE; POSTOPERATIVE THROMBOSIS; PRIMARY PREVENTION; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STOMACH TUMOR; THROMBIN TIME; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ARTICLE; COMORBIDITY; EVIDENCE BASED MEDICINE; PREVALENCE; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

COMORBIDITY; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84866173573     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1173     Document Type: Review

References (55)

1. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17-I21.
2. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-4907.
3. Ay C, Simanek R, Vormittag R et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008;112:2703-2708.
4. Kawaguchi T, Kumabe T, Kanamori M et al. Early detection of venous thromboembolism in patients with neuroepithelial tumor: efficacy of screening with serum D-dimer measurements and Doppler ultrasonography. J Neurooncol 2011;101:495-504.
5. Beck-Razi N, Kuzmin A, Koren D et al. Asymptomatic deep vein thrombosis in advanced cancer patients: the value of venous sonography. J Clin Ultrasound 2010;38:232-237.
6. Satoh T, Oki A, Uno K et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 2007;97:1053-1057.
7. Heidrich H, Konau E, Hesse P. Asymptomatic venous thrombosis in cancer patients--a problem often overlooked. Results of a retrospective and prospective study. Vasa 2009;38:160-166.
8. Sorensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
9. Alcalay A, Wun T, Khatri V et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006;24:1112-1118.
10. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334-1349.
11. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
12. Khorana AA, Francis CW, Culakova E et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-2346.
13. Ay C, Vormittag R, Dunkler D et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009;27:4124-4129.
14. Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722.
15. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.
16. Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-464.
17. Numico G, Garrone O, Dongiovanni V et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005;103:994-999.
18. Mandala M, Barni S, Prins M et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010;21:871-876.
19. Simanek R, Vormittag R, Ay C et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010;8:114-120.
20. Sparsa A, Durox H, Doffoel-Hantz V et al. High prevalence and risk factors of thromboembolism in stage IV melanoma. J Eur Acad Dermatol Venereol 2011;25:340-344.
21. Chew HK, Davies AM, Wun T et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601-608.
22. Blom JW, Vanderschoot JP, Oostindier MJ et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4:529-535.
23. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010;102 (Suppl 1):S2-S9.
24. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-1615.
25. Urbauer E, Kaufmann H, Nosslinger T et al. Thromboembolic events during treatment with thalidomide. Blood 2002;99:4247-4248.
26. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009;27:4848-4857.
27. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-2285.
28. Hapani S, Sher A, Chu D et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010;79:27-38.
29. Kakkar AK. Prevention of venous thromboembolism in the cancer surgical patient. J Clin Oncol 2009;27:4881-4884.
30. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008;133:381S-453S.
31. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505.
32. Bottaro FJ, Elizondo MC, Doti C et al. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A metaanalysis. Thromb Haemost 2008;99:1104-1111.
33. Akl EA, Terrenato I, Barba M et al. Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. Thromb Haemost 2008;100:1176-1180.
34. Khorana AA, Francis CW, Culakova E et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-2829.
35. Kroger K, Weiland D, Ose C et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297-303.
36. Kanz R, Vukovich T, Vormittag R et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011;9:57-63.
37. Ay C, Jungbauer LV, Sailer T et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 2007;53:1235-1243.
38. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746-756.
39. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
40. Zurborn KH, Duscha H, Gram J et al. Investigations of coagulation system and fibrinolysis in patients with disseminated adenocarcinomas and non-Hodgkin's lymphomas. Oncology 1990;47:376-380.
41. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005;31:104-110.
42. Koster T, Blann AD, Briet E et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-155.
43. Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-462.
44. Vormittag R, Simanek R, Ay C et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009;29:2176-2181.
45. Thaler J, Ay C, Weinstabl H et al. Circulating procoagulant microparticles in cancer patients. Ann Hematol 2011;90:447-453.
46. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995;74:134-138.
47. Lutsey PL, Folsom AR, Heckbert SR et al. Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost 2009;7:1639-1648.
48. Hron G, Kollars M, Binder BR et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006;296:397-402.
49. Ay C, Dunkler D, Simanek R et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011;29:2099-2103.
50. Ay C, Dunkler D, Marosi C et al. Prediction of venous thromboembolism in cancer patients. Blood. 116:5377-5382.
51. Levine M, Hirsh J, Gent M et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-889.
52. Perry JR, Julian JA, Laperriere NJ et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010;8:1959-1965.
53. Agnelli G, Gussoni G, Bianchini C et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-949.
54. Riess H, Pelzer U, Hilbig A et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer 2008;8:361.
55. Riess A et al. Data presented at the congress of the ISTH in Boston, 2009.